Health ❯Healthcare ❯Clinical Trials

Phase 3 Trials

FDA Microbiology Pharmaceuticals Clinical Trials Medication Adherence Bacterial Infections Diabetes Investments Cancer Treatment Drug Competition

4 ARTICLES

last mo.

Amgen’s MariTide Delivers 20% Weight Loss in Phase 2 and Advances to 72-Week Phase 3 Trial

Amgen plans a 72-week pivotal study following phase 2 results that showed substantial weight loss alongside lower gastrointestinal side effects from a low-dose ramp-up.

6 ARTICLES

last mo.

Novo Nordisk’s CagriSema Delivers 20.4% Weight Loss, Shares Drop

4 ARTICLES

last mo.

Eli Lilly’s Oral GLP-1 Pill Matches Injectables in Weight and Blood Sugar Control

6 ARTICLES

last mo.

FDA Expands Moderna RSV Vaccine to Adults 18–59 at Risk

4 ARTICLES

last mo.

Inherited Mitochondrial Variant Linked to Checkpoint Inhibitor Resistance in Metastatic Melanoma

6 ARTICLES

2mo ago

Sanofi and J&J Halt E. coli Vaccine Trial After Insufficient Efficacy

Phase 3 Trials

Amgen’s MariTide Delivers 20% Weight Loss in Phase 2 and Advances to 72-Week Phase 3 Trial

Novo Nordisk’s CagriSema Delivers 20.4% Weight Loss, Shares Drop

Eli Lilly’s Oral GLP-1 Pill Matches Injectables in Weight and Blood Sugar Control

FDA Expands Moderna RSV Vaccine to Adults 18–59 at Risk

Inherited Mitochondrial Variant Linked to Checkpoint Inhibitor Resistance in Metastatic Melanoma

Triplet Therapy Doubles Survival in BRAF V600E Metastatic Colorectal Cancer

Moderna Withdraws Flu-COVID Vaccine Application After FDA Requests More Data

FDA Reviews Pembrolizumab for Transformative Head and Neck Cancer Treatment

UK Grants First Global Approval for GSK’s Blenrep in Two Combination Therapies

EU Regulators Reject Eli Lilly's Alzheimer's Drug Over Safety Concerns

FDA Approves VYKAT XR, First Therapy for Hyperphagia in Prader-Willi Syndrome

Sanofi and J&J Halt E. coli Vaccine Trial After Insufficient Efficacy